Delivery Order SPE2DE21D0005-SPE2D625F6P6F
- Not listed
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 30, 2025, with an ultimate completion date of June 4, 2025, utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 for APLIGRAF on May 30, 2025, with an ultimate completion date of June 4, 2025. This fixed-price contract with economic price adjustment was issued by the Medical Supply Chain, a defense-focused federal agency, with no set-aside designation applied. APLIGRAF is an advanced wound care and tissue regeneration product that falls within Organogenesis's core portfolio...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,239.95 Delivery Order (SPE2DE21D0005|SPE2D625F228P) to Organogenesis Inc., a for-profit manufacturer of regenerative medicine products. The award is for the delivery of the advanced wound care product APLIGRAF. The order is a Fixed Price with Economic Price Adjustment contract with a completion date of November 1, 2024. Organogenesis, headquartered in Canton, Massachusetts, is a key supplier of medical products to federal...
- On May 12, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,239.95 to Organogenesis Inc. for APLIGRAF, an advanced regenerative medicine product used in wound care and tissue regeneration. The contract is classified as fixed price with economic price adjustment and carries an ultimate completion date of May 15, 2025. This delivery order was issued without set-aside designation, reflecting Organogenesis's status as a standard commercial vendor...
- This is a federal contract award to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the delivery of APLIGRAF, a skin substitute product. The contract is a Delivery Order, with a Ceiling Value of $1,239.95, and a Fixed Price with Economic Price Adjustment pricing type. The contract has an Ultimate Completion Date of April 17, 2025. Organogenesis Inc. is a for-profit...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts. The award, valued at $1,239.95, is for the delivery of APLIGRAF, a skin substitute product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) vehicle held by Organogenesis with the DLA, valued at $49.5 million, for wound care dressings and medical supplies. This IDC was awarded as a total small...
- This is a $1,239.95 fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Organogenesis Inc., a regenerative medicine company. The order is for the company's APLIGRAF product, which is a wound dressing and tissue regeneration solution. Organogenesis has been awarded numerous prime federal contracts by the DLA and Department of Veterans Affairs (VA) to provide advanced wound care and surgical products. This specific award is not associated with a set-aside program....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The $1,239.95 fixed-price delivery order is for the supply of APLIGRAF, a skin substitute product, to support wound care and tissue regeneration for military personnel and veterans. Organogenesis is an established vendor for the Department of Veterans Affairs (VA) and DLA, holding several significant federal...
- This federal contract award to Organogenesis Inc., a leading regenerative medicine company, is for the delivery of APLIGRAF, a wound care product, to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,239.95 fixed-price delivery order, which includes an economic price adjustment, has a completion date of June 11, 2024. Organogenesis Inc. is a for-profit manufacturer of goods and has been a registered federal contractor since 2006. The company holds several significant Indefinite...
- SPE2DE21D0005Indefinite Delivery Contract
- SPE2DE21D0005-SPE2D625F6P6FDelivery Order
Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis competed as a standard commercial vendor. This delivery order is issued under one of Organogenesis's larger contract vehicles with the Defense Logistics Agency—a $49.5 million multiple-award Indefinite Delivery Contract for medical equipment and supplies running through June 2026. The company serves as a key supplier of regenerative medicine solutions to federal healthcare programs supporting military personnel and veterans, leveraging its portfolio of advanced wound care dressings and surgical biologics across several significant indefinite delivery vehicles with both the DLA and the Department of Veterans Affairs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 5/7/25 |